Angiogenesis and immune checkpoint dual blockade in combination with radiotherapy for treatment of solid cancers: opportunities and challenges

Several immune checkpoint blockades (ICBs) capable of overcoming the immunosuppressive roles of the tumor immune microenvironment have been approved by the US Food and Drug Administration as front-line treatments of various tumor types. However, due to the considerable heterogeneity of solid tumor c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Lingling, Yu, Xianzhe, Wang, Li, Liu, Jiewei, Qu, Zihan, Zhang, Honge, Li, Lu, Chen, Jiang, Zhou, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272720/
https://www.ncbi.nlm.nih.gov/pubmed/34247198
http://dx.doi.org/10.1038/s41389-021-00335-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272720/
https://www.ncbi.nlm.nih.gov/pubmed/34247198
http://dx.doi.org/10.1038/s41389-021-00335-w

Ejemplares similares